Hepatocellular Cancer Recruiting Phase 2 Trials for Aldesleukin (DB00041)

Also known as: Cancer, Hepatocellular

IndicationStatusPhase
DBCOND0037277 (Hepatocellular Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01967823T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing CancerTreatment